Harry Cassin
Publisher and Editor
Andy Spalding
Senior Editor
Jessica Tillipman
Senior Editor
Bill Steinman
Senior Editor
Richard L. Cassin
Editor at Large
Elizabeth K. Spahn
Editor Emeritus
Cody Worthington
Contributing Editor
Julie DiMauro
Contributing Editor
Thomas Fox
Contributing Editor
Marc Alain Bohn
Contributing Editor
Bill Waite
Contributing Editor
Shruti J. Shah
Contributing Editor
Russell A. Stamets
Contributing Editor
Richard Bistrong
Contributing Editor
Eric Carlson
Contributing Editor
At the 17th Annual Pharmaceutical and Medical Device Compliance Congress last month in Washington DC, Paul Hastings Partner Gary Giampetruzzi and FCPA Blog Contributing Editor Richard Bistrong exchanged perspectives on pharma compliance risks.
Their panel was “Behind the Bribe: Multiple Real World Perspectives on How Foreign Bribery Occurs, Is Investigated, and Could Be Prevented.”
Here’s a 15-minute clip of the discussion.
2 Comments
At the risk of sounding naive, how about a "zero tolerance" policy directive from leadership, including the BOD?
How about the billions that are paid in bribes by Amgen to medical service providers here in the US? Paul Hastings aides and abetts this activity as their counsel. As a whistleblower I helped recover $780 million for taxpayers while AMGEN and Paul Hastings threatened to take my wife's disability away. Currently in NY I have a case to recover $7 billion that Amgen in a hub and spoke conspiracy defrauded Medicare and Medicaid. AMGEN and Paul Hastings have done everything possible to cover up this horrific corruption.
Comments are closed for this article!